Abstract: The present invention relates to benzsulfonamide derivatives of formula I and methods of use thereof. The benzsulfonamide derivatives of the present invention are efficient modulators of the JNK pathway. In particular the benzsulfonamide derivatives of the present invention are selective inhibitors of JNK 2 and 3.
Type:
Grant
Filed:
June 19, 2008
Date of Patent:
August 30, 2011
Assignee:
Merck Serono SA
Inventors:
Serge Halazy, Dennis Church, Stephen J. Arkinstall, Marco Biamonte, Montserrat Camps, Jean-Pierre Gotteland, Thomas Rueckle
Abstract: The present invention relates to the use of IL-6 or a fragment, variant, fusion protein, functional derivative or salt thereof in microvascular complications.
Type:
Grant
Filed:
August 30, 2005
Date of Patent:
August 23, 2011
Assignee:
Merck Serono SA
Inventors:
Michel Dreano, Pierre-Alain Vitte, Norman Cameron, Mary A. Cotter
Abstract: The invention relates to active fragments of the IL-18 binding protein, to pharmaceutical compositions comprising such active fragments, and to medical uses thereof.
Abstract: The present invention is related to derivatives of Formula (I) and use thereof in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis.
Type:
Grant
Filed:
December 19, 2005
Date of Patent:
July 5, 2011
Assignee:
Merck Serono SA
Inventors:
Dominique Swinnen, Agnes Bombrun, Patrick Gerber, Catherine Jorand-Lebrun
Abstract: A dispenser for the delivery of medication includes: a support (9, 10) supporting an array of blister(s) (11) each containing a medication dose, the support (9, 10) having an array of through hole(s) (19, 25) below the blister(s) (11) respectively, an actuating member (13) located above the support (9, 10), the actuating member (13) being movable in translation relative to the support (9, 10), by at least one step, in a determined direction (d) parallel to the support (9, 10), and elements (29, 57) for converting each of the step(s) of translational motion of the actuating member (13) into a pressure exerted on corresponding one(s) of the blister(s) (11) towards the corresponding through hole(s) (19, 25) to expel the corresponding medication dose(s) through the corresponding through hole(s) (19, 25).
Abstract: The invention provides novel, substituted 3-arylamino pyridine compounds (I) pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.
Abstract: FSH mutant with increased glycosylation and longer half-life is described. The use of this FSH mutant for inducing folliculogenesis in human patients is also described.
Type:
Grant
Filed:
January 16, 2007
Date of Patent:
June 7, 2011
Assignee:
Merck Serono SA
Inventors:
Marco Muda, Xuliang Jiang, Sean D. McKenna
Abstract: The present invention relates to the use of IL-6 in compositions and methods for therapy or prevention of chemotherapy-induced neuropathy (CIPN). More specifically, the invention relates to the use of a low dose of IL-6 for the treatment and/or prevention CIPN.
Abstract: The present invention is related to carboxylic acids of Formula (I) and use thereof for the treatment and/or prevention of obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of carboxylic acids of Formula (I) to modulate, notably to inhibit the activity of PTPs.
Abstract: The present invention relates to the use of genetic markers to identify the response to interferon-beta (IFN-beta) treatment in Multiple Sclerosis (MS) patients as well as a method for treating MS patients and kits for genotyping.
Abstract: This invention refers to industrial production of proteins. More particularly, the invention refers to a fusion protein as a novel chimeric selection marker comprising a peptide conferring resistance to an antibiotic, or a fragment, allelic variant, splice variant or mutein thereof, and at least one sequence comprising SEQ ID NO: 1, 2 or 3, preferably for producing a protein of interest (POI). The inventive chimeric selection marker exhibits: (i) a resistance to an antibiotic; and (ii) a fluorescence activity upon binding of a ligand to the sequence comprising SEQ ID NO: 1, 2 or 3. The invention further refers to nucleic acids encoding the inventive fusion protein and to expression vectors, comprising the inventive fusion protein and additionally the protein of interest (POI). Finally, uses of the inventive chimeric selection marker for screening cells for high expression of a protein of interest (POI) are disclosed.
Abstract: The present invention discloses peptides isolated from the extracellular domain of OX40 Ligand (OX40L) capable of binding OX40 Receptor (OX40R) and inhibiting OX40R-OX40L interaction. Such peptides, fusion proteins comprising them, as well as peptides and other molecules designed on their sequences, can be used as OX40R binding agents competing with natural OX40L for blocking OX40R-mediated cell signaling in the prophylaxis and/or treatment of diseases related to activated T cells.
Abstract: The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.
Type:
Application
Filed:
November 23, 2010
Publication date:
April 14, 2011
Applicant:
MERCK SERONO SA
Inventors:
Anna Quattropani, David Covini, Vincent Pomel, Jerome Dorbais, Thomas Rueckle
Abstract: The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.
Type:
Application
Filed:
November 23, 2010
Publication date:
March 24, 2011
Applicant:
MERCK SERONO SA
Inventors:
Anna Quattropani, David Covini, Vincent Pomel, Jérôme Dorbais, Thomas Rueckle
Abstract: The child-resistant medication container includes: a housing having an open end, a support slidably mounted in the housing for supporting medication, first locking element for locking the support in the housing and for unlocking the support so that the support may be slid to the outside of the housing through the open end, the first locking element including a first locking member coupled to the housing and a second locking member coupled to the support, the first and second locking members being engageable with each other, and at least one button operable to act on the first locking element, the at least one button including a first button operable to disengage the first and second locking members, second locking element for maintaining engagement between the first and second locking members, and a second button operable to act on the second locking element to permit disengaging the first and second locking members by operating the first button.
Abstract: The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.
Type:
Grant
Filed:
May 24, 2006
Date of Patent:
February 15, 2011
Assignee:
Merck Serono SA
Inventors:
Anna Quattropani, David Covini, Vincent Pomel, Jerome Dorbais, Thomas Rueckle
Abstract: The invention relates to compounds of formula I wherein R1, R2, R4, Ra, Rb, Rc, Re, A*, W1, W2 and W3 are as defined in claim 16, for the treatment of CXCR3 related diseases.
Type:
Application
Filed:
April 8, 2009
Publication date:
February 3, 2011
Applicant:
MERCK SERONO SA
Inventors:
Stefano Crosignani, Christophe Cleva, Christos Tsaklakidis, Lars Burgdorf
Abstract: The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.
Type:
Grant
Filed:
May 24, 2006
Date of Patent:
February 1, 2011
Assignee:
Merck Serono SA
Inventors:
Anna Quattropani, David Covini, Vincent Pomel, Jerome Dorbais, Thomas Rueckle
Abstract: The present invention is related to sulfonamide derivatives of Formula (Ia) where the groups are as defined in the description, and use thereof in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis.
Type:
Grant
Filed:
October 24, 2006
Date of Patent:
February 1, 2011
Assignee:
Merck Serono SA
Inventors:
Patrick Gerber, Dominique Swinnen, Agnes Bombrun
Abstract: The present invention relates to the use of PTPH1 inhibitors in the prevention or treatment of Alzheimer's Disease, or a symptom thereof. The present invention also relates to a method of identifying compounds useful in the prevention or treatment of Alzheimer's Disease, or a symptom thereof.